Literature DB >> 7329558

Surgery on pituitary adenomas in patients in a subarctic region.

S H Nyström, H S Rönty, E R Heikkinen, M J Heiskari, J Laitinen, K K Tulkki.   

Abstract

The present series consists of 18 consecutive patients with pituitary adenomas operated on between 1977 and 1979 using the transfrontal route. Ten adenomas were 10, 20 or 30 times the normal maximum size of the pituitary measured according to Di Chiro and Nelson's (2) index (Table 2). Tumours without obvious suprasellar growth were operated on using the trans-sphenoidal route and thus are not included in the present series. Large and giant pituitary adenomas are preferably removed by the transfrontal route and using microsurgical techniques. Really poor vision associated with very large tumours seem to improve but not to normal level. A blind eye stays blind. Less poor vision returns to normal (Table 4). Prolactin values associated with giant prolactinomas are extremely high and may remain raised even after apparently radical extirpation. Isolated tumour-containing sellar crypts associated with these large tumours may be responsible for this observation. Postoperative radiotherapy and bromocriptine administration therefore seem advisable. Further operations may be necessary on patients with extensive posterior or lateral growths. Redundant partially intraosseous tumour fragments may be more easily removed later, possibly owing to the beneficial effects of radiation therapy. It is hoped that large and giant adenomas in the future will pass into history, even in the peripheral parts of the world. The trans-sphenoidal approach is always a better solution than the transfrontal approach whenever it can be carried out, but it requires earlier diagnosis.

Entities:  

Mesh:

Year:  1981        PMID: 7329558     DOI: 10.1007/bf01743706

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  10 in total

1.  The volume of the sella turcica.

Authors:  G DI CHIRO; K B NELSON
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-06

2.  Transcranial management of pituitary tumours with suprasellar extension.

Authors:  L Symon; J Jakubowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

3.  Intracranial removal of pituitary adenomas. An evaluation of varying degree of excision from partial to total.

Authors:  W E Stern; U Batzdorf
Journal:  J Neurosurg       Date:  1970-11       Impact factor: 5.115

4.  Successful treatment of acromegaly: metabolic and clinical studies in 145 patients.

Authors:  J H Lawrence; C A Tobias; J A Linfoot; J L Born; J T Lyman; C Y Chong; E Manougian; W C Wei
Journal:  J Clin Endocrinol Metab       Date:  1970-08       Impact factor: 5.958

5.  Metrizamide cisternography in the evaluation of pituitary adenomas and the empty sella syndrome.

Authors:  C E Gross; E F Binet; J V Esguerra
Journal:  J Neurosurg       Date:  1979-04       Impact factor: 5.115

6.  Surgical experience with chromophobe adenomas of the pituitary gland.

Authors:  B S Ray; R H Patterson
Journal:  J Neurosurg       Date:  1971-06       Impact factor: 5.115

7.  Reduction in size of a pituitary tumor by bromocriptine therapy.

Authors:  A M McGregor; M F Scanlon; K Hall; D B Cook; R Hall
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

8.  The specificity of serum prolactin as a diagnostic indicator of pituitary adenoma.

Authors:  S Balagura; A G Frantz; E M Housepian; P W Carmel
Journal:  J Neurosurg       Date:  1979-07       Impact factor: 5.115

9.  Indications for angiography in the preoperative evaluation of patients with prolactin-secreting pituitary adenomas.

Authors:  I L Richmond; T H Newton; C B Wilson
Journal:  J Neurosurg       Date:  1980-03       Impact factor: 5.115

10.  Follow-up study with computerized tomography and clinical evaluation 5 to 10 years after surgery for pituitary adenoma.

Authors:  C Muhr; K Bergstrom; P Enoksson; R Hugosson; P O Lundberg
Journal:  J Neurosurg       Date:  1980-08       Impact factor: 5.115

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.